Key risks
- PE multiple 87.07 elevated; verify earnings growth trajectory and quality justify valuation
- Revenue ₹383–₹610 Cr and EPS ₹1.65–₹6.76 volatile across quarters; verify source of volatility and sustainability
- FII holding 2.58% (down from 1.28% six months prior) while promoter holds 71.42%; verify barriers to foreign institutional investment or lack of appeal
- Biotech-specific: verify pipeline depth, regulatory approval timelines, patent cliffs in core therapies, geographic revenue concentration
Generated analysis · source review pending